caa a22 4500 445332883 CHVBK 20180317142743.0 cr unu---uuuuu 170323e20110101xx s 000 0 eng 10.1245/s10434-010-1192-z doi (NATIONALLICENCE)springer-10.1245/s10434-010-1192-z Update on DCIS Outcomes from the American Society of Breast Surgeons Accelerated Partial Breast Irradiation Registry Trial [Elektronische Daten] [Jacqueline Jeruss, Henry Kuerer, Peter Beitsch, Frank Vicini, Martin Keisch] Background: Since the initial reports on use of MammoSite accelerated partial breast irradiation (APBI) for treatment of ductal carcinoma in situ (DCIS), additional follow-up data were collected. We hypothesized that APBI delivered via MammoSite would continue to be well tolerated, associated with a good cosmetic outcome, and carry a low risk for recurrence in patients with DCIS. Materials and Methods: From 2002-2004, 194 patients with DCIS were enrolled in a registry trial to assess the MammoSite. Follow-up data were available for all 194 patients. Median follow-up was 54.4months; 63 patients had at least 5years of follow-up. Data obtained included patient-, tumor-, and treatment-related factors, and recurrence incidence. Results: Of the 194 patients, 87 (45%) had the MammoSite placed at lumpectomy; 107 patients (55%) had the device placed postlumpectomy. In the first year of follow-up, 16 patients developed a breast infection, though the method of device placement was not associated with infection risk. Also, 46 patients developed a seroma that was associated with applicator placement at the time of lumpectomy (P=0.001). For patients with at least 5years of follow-up, 92% had favorable cosmetic results. There were 6 patients (3.1%) who had an ipsilateral breast recurrence, with 1 (0.5%) experiencing recurrence in the breast and axilla, for a 5-year actuarial local recurrence rate of 3.39%. Conclusions: During an extended follow-up period, APBI delivered via MammoSite continued to be well tolerated for patients with DCIS. Use of this device may make lumpectomy possible for patients who would otherwise choose mastectomy because of barriers associated with standard radiation therapy. Society of Surgical Oncology, 2010 Jeruss Jacqueline Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA aut Kuerer Henry Department of Surgical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA aut Beitsch Peter Department of Surgery, Dallas Breast Center, Dallas, TX, USA aut Vicini Frank Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, MI, USA aut Keisch Martin Radiation Oncology, Aventura Comprehensive Cancer Center, Aventura, FL, USA aut Annals of Surgical Oncology Springer-Verlag 18/1(2011-01-01), 65-71 1068-9265 18:1<65 2011 18 10434 https://doi.org/10.1245/s10434-010-1192-z text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1245/s10434-010-1192-z text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Jeruss Jacqueline Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA aut NATIONALLICENCE 700 1- Kuerer Henry Department of Surgical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA aut NATIONALLICENCE 700 1- Beitsch Peter Department of Surgery, Dallas Breast Center, Dallas, TX, USA aut NATIONALLICENCE 700 1- Vicini Frank Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, MI, USA aut NATIONALLICENCE 700 1- Keisch Martin Radiation Oncology, Aventura Comprehensive Cancer Center, Aventura, FL, USA aut NATIONALLICENCE 773 0- Annals of Surgical Oncology Springer-Verlag 18/1(2011-01-01), 65-71 1068-9265 18:1<65 2011 18 10434 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer